TD Private Client Wealth’s Intellia Therapeutics NTLA Stock Holding History

TD Private Client Wealth’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42K	Hold	84	–	–	﹤0.01%	1418
2026 Q1	$1.08K	Hold	84	–	–	﹤0.01%	1374
2025 Q4	$755	Sell	84 -42	-33%	-$578	﹤0.01%	1422
2025 Q3	$2.18K	Buy	126 +42	+50%	+$517	﹤0.01%	1239
2025 Q2	$788	Buy	+84	New	+$690	﹤0.01%	1315
2021 Q4	–	Sell	-9	Closed	-$1.21K	–	1237
2021 Q3	$1.21K	Hold	9	–	–	﹤0.01%	1078
2021 Q2	$1.46K	Buy	+9	New	+$701	﹤0.01%	1065

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

TD Private Client Wealth's NTLA Position: Q2 2026 in Review

TD Private Client Wealth held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 84 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1418.

TD Private Client Wealth first reported a position in NTLA in Q2 2021 and has held it in 7 quarters since. The position peaked at $2.18K in Q3 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

TD Private Client Wealth held 84 shares of Intellia Therapeutics worth $1.42K as of Q2 2026.
TD Private Client Wealth left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1418 holding.
TD Private Client Wealth first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 7 quarters since.
TD Private Client Wealth's Intellia Therapeutics position peaked at $2.18K in Q3 2025.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.